The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC).
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Stefan Kasper
Employment - University Hospital Essen (I)
Honoraria - Amgen; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Incyte; Janssen-Cilag; Lilly; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; BMS; Lilly; Merck Serono; Pierre Fabre; Roche; Sanofi
Other Relationship - Amgen; Bristol-Myers Squibb; Lilly; Merck Serono; Roche; Sanofi
 
Fernando Rivera
Stock and Other Ownership Interests - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; SERVIER
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; SERVIER
Research Funding - Amgen; Amgen (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Lilly; Lilly (Inst); Merck Serono; Merck Serono (Inst); MSD; MSD (Inst); Novartis; Novartis (Inst); Roche; Roche (Inst); Sanofi; Sanofi (Inst); SERVIER; SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; SERVIER
 
Christophe Tournigand
Honoraria - Bayer; Bristol-Myers Squibb; MSD; Roche; Sanofi
Consulting or Advisory Role - Bayer
Research Funding - Roche
Travel, Accommodations, Expenses - Bayer; MSD; Roche
 
Yuan Cheng
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Priya Deshpande
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Denise D'Alessio
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Nabil Amirouchene Angelozzi
Employment - Novartis
Travel, Accommodations, Expenses - Janssen
 
Ana Bento Pereira da Silva
Employment - Novartis
Stock and Other Ownership Interests - Novartis; Roche
 
Neil Howard Segal
Consulting or Advisory Role - ABL Bio; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Numab; PureTech; Revitope
Research Funding - AstraZeneca; Bristol-Myers Squibb; Immunocore; Merck; Pfizer; PureTech (Inst); Regeneron (Inst); Roche/Genentech